SECTION 1: IDENTIFICATION

1.1. Product Identifier
Product Form: Mixture
Product Name: Adenocard® IV (Adenosine) Injection
Material Name: Adenosine
Formula: C_{10}H_{13}N_{5}O_{4}
Chemical Name of Active Ingredient: 6-amino-9-β-D-ribofuranosyl-9-H-purine

1.2. Intended Use of the Product
Use of the substance/mixture: A pharmacologic stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

1.3. Name, Address, and Telephone of the Responsible Party
Company
Astellas US LLC
1 Astellas Way
Northbrook, IL 60062
Tel.: 800-888-7704
www.us.astellas.com

1.4. Emergency Telephone Number
Emergency Number: 800-727-7003 Medical Communications

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the Substance or Mixture
Classification (GHS-US)
Not classified

2.2. Label Elements
GHS-US Labeling
No labeling applicable

2.3. Other Hazards
Exposure may aggravate those with pre-existing eye, skin, or respiratory conditions. May cause exacerbation of asthma. May cause second or third degree heart block.

2.4. Unknown Acute Toxicity (GHS-US)
No data available

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substance
Not applicable

3.2. Mixture

<table>
<thead>
<tr>
<th>Name</th>
<th>Product Identifier</th>
<th>%</th>
<th>Classification (GHS-US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>(CAS No) 7732-18-5</td>
<td>98.8</td>
<td>Not classified</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>(CAS No) 7647-14-5</td>
<td>0.9</td>
<td>Not classified</td>
</tr>
<tr>
<td>Adenosine</td>
<td>(CAS No) 58-61-7</td>
<td>0.3</td>
<td>Not classified</td>
</tr>
</tbody>
</table>

Full text of H-phrases: see section 16

SECTION 4: FIRST AID MEASURES

4.1. Description of First Aid Measures
First-aid Measures General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label if possible).
First-aid Measures After Inhalation: Remove to fresh air and keep at rest in a position comfortable for breathing. Obtain medical attention if breathing difficulty persists.
First-aid Measures After Skin Contact: Rinse immediately with plenty of water. Obtain medical attention if irritation develops or persists.
First-aid Measures After Eye Contact: Rinse cautiously with water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention.
First-aid Measures After Ingestion: Do NOT induce vomiting. Rinse mouth. Immediately call a POISON CENTER or doctor/physician.
Adenocard® IV (Adenosine) Injection
Safety Data Sheet

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

4.2. Most important symptoms and effects, both acute and delayed
Symptoms/Injuries: Not expected to present a significant hazard under anticipated conditions of normal use.
Symptoms/Injuries After Inhalation: May cause exacerbation of asthma.
Symptoms/Injuries After Skin Contact: May cause skin irritation.
Symptoms/Injuries After Eye Contact: May cause eye irritation.
Symptoms/Injuries After Ingestion: Gastrointestinal irritation.
Symptoms/Injuries After Accidental Injection: Flushing, chest discomfort, dyspnea or urge to breathe deeply, headache, throat, neck or jaw discomfort, gastrointestinal discomfort, lightheadedness/dizziness, upper extremity discomfort, atrial fibrillation, ST segment depression, first-degree atrio-ventricular (AV) block; second-degree AV block, paresthesia, hypotension, nervousness and arrhythmias.

Chronic Symptoms: None expected under normal conditions of use.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed
If you feel unwell, seek medical advice (show the label where possible).

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media
Suitable Extinguishing Media: Use extinguishing media appropriate for surrounding fire.
Unsuitable Extinguishing Media: Do not use a heavy water stream. Use of heavy stream of water may spread fire.
5.2. Special Hazards Arising From the Substance or Mixture
Fire Hazard: Not flammable.
Explosion Hazard: Product is not explosive.
Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters
Precautionary Measures Fire: Exercise caution when fighting any chemical fire.
Firefighting Instructions: Use water spray or fog for cooling exposed containers.
Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.
Other Information: Refer to Section 9 for flammability properties.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures
General Measures: Avoid all contact with skin, eyes, or clothing. Avoid breathing (vapor, mist, spray).
6.1.1. For Non-emergency Personnel
Protective Equipment: Use appropriate personal protection equipment (PPE).
6.1.2. For Emergency Responders
Protective Equipment: Equip cleanup crew with proper protection.
Emergency Procedures: Stop leak if safe to do so. Ventilate area.
6.2. Environmental Precautions
Prevent entry to sewers and public waters. Notify authorities if liquid enters sewers or public waters.

6.3. Methods and Material for Containment and Cleaning Up
For Containment: Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams.
Methods for Cleaning Up: Clear up spills immediately and dispose of waste safely. Spills should be contained with mechanical barriers. Transfer spilled material to a suitable container for disposal. Contact competent authorities after a spill.
6.4. Reference to Other Sections
See Heading 8. Exposure controls and personal protection. For further information refer to section 13.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling
Hygiene Measures: Handle in accordance with good industrial hygiene and safety procedures. Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work.

7.2. Conditions for Safe Storage, Including Any Incompatibilities
Technical Measures: Comply with applicable regulations.
Storage Conditions: Store in a dry, cool and well-ventilated place. Keep container closed when not in use. Do not refrigerate; protect from freezing.
Storage Temperature: 15 - 30 °C (59 - 86 °F)
7.3. Specific End Use(s)
A pharmacologic stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

SECTION 8: EXPOSURE CONTROLS/PERSORAL PROTECTION

8.1. Control Parameters
For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), NIOSH (REL), or OSHA (PEL).

8.2. Exposure Controls
Appropriate Engineering Controls : Ensure adequate ventilation, especially in confined areas. Emergency eye wash fountains and safety showers should be available in the immediate vicinity of any potential exposure. Ensure all national/local regulations are observed.


Materials for Protective Clothing : Chemically resistant materials and fabrics.
Hand Protection : Wear chemically resistant protective gloves.
Eye Protection : Chemical goggles or safety glasses.
Skin and Body Protection : Wear suitable protective clothing.
Respiratory Protection : In case of insufficient ventilation, wear suitable respiratory equipment.
Environmental Protection Controls : Do not allow the product to be released into the environment.
Consumer Exposure Controls : Do not eat, drink or smoke during use.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties
Physical State : Liquid
Appearance : Clear solution
Odor : None
Odor Threshold : No data available
pH : 4.5 - 7.5
Evaporation Rate : No data available
Melting Point : 234 - 235 °C (453 - 455 °F) (Adenosine)
Freezing Point : No data available
Boiling Point : No data available
Flash Point : No data available
Auto-ignition Temperature : No data available
Decomposition Temperature : No data available
Flammability (solid, gas) : No data available
Vapor Pressure : No data available
Relative Vapor Density at 20 °C : No data available
Relative Density : No data available
Solubility : Soluble in water
Partition Coefficient: N-Octanol/Water : No data available
Viscosity : No data available
Molecular Weight : 267.24 (Adenosine)

9.2. Other Information : No additional information available.

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity : Hazardous reactions will not occur under normal conditions.
10.2. Chemical Stability : Stable under recommended handling and storage conditions (see section 7).
10.3. Possibility of Hazardous Reactions : Hazardous polymerization will not occur.
Adenocard® IV (Adenosine) Injection
Safety Data Sheet
According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations


10.5. Incompatible Materials: Strong acids, strong bases, strong oxidizers.


SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information On Toxicological Effects

Acute Toxicity: Not classified

### Sodium chloride (7647-14-5)

<table>
<thead>
<tr>
<th>LD50 Oral Rat</th>
<th>3 g/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LC50 Inhalation Rat</td>
<td>&gt; 42 g/m³ (Exposure time: 1 h)</td>
</tr>
</tbody>
</table>

Skin Corrosion/Irritation: Not classified (pH: 4.5 - 7.5)

Serious Eye Damage/Irritation: Not classified (pH: 4.5 - 7.5)

Respiratory or Skin Sensitization: Not classified

Germ Cell Mutagenicity: Not classified (Adenosine was negative in the Salmonella/Mammalian-Microsome Plate Incorporation Mutagenicity Assay.)

Carcinogenicity: Not classified (Studies in animals have not been performed to evaluate the carcinogenic potential of Adenocard [adenosine injection].)

Reproductive Toxicity: Not classified (Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. As adenosine is a naturally occurring material, widely dispersed throughout the body, no fetal effects would be anticipated. However, since it is not known whether Adenocard can cause fetal harm when administered to pregnant women, Adenocard should be used during pregnancy only if clearly needed.)

Specific Target Organ Toxicity (Single Exposure): Not classified

Specific Target Organ Toxicity (Repeated Exposure): Not classified

Aspiration Hazard: Not classified

Symptoms/Injuries After Inhalation: May cause exacerbation of asthma.

Symptoms/Injuries After Skin Contact: May cause skin irritation.

Symptoms/Injuries After Eye Contact: May cause eye irritation.

Symptoms/Injuries After Ingestion: Gastrointestinal irritation.

Symptoms/Injuries After Accidental Injection: Flushing, chest discomfort, dyspnea or urge to breathe deeply, headache, throat, neck or jaw discomfort, gastrointestinal discomfort, lightheadedness/dizziness, upper extremity discomfort, atrial fibrillation, ST segment depression, first-degree atrio-ventricular (AV) block; second-degree AV block, paresthesia, hypotension, nervousness and arrhythmias.

Chronic Symptoms: None expected under normal conditions of use.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

### Sodium chloride (7647-14-5)

<table>
<thead>
<tr>
<th>LC50 Fish 1</th>
<th>5560 (5560 - 6080) mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [flow-through])</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC50 Daphnia 1</td>
<td>1000 mg/l (Exposure time: 48 h - Species: Daphnia magna)</td>
</tr>
<tr>
<td>LC 50 Fish 2</td>
<td>12946 mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [static])</td>
</tr>
<tr>
<td>EC50 Daphnia 2</td>
<td>340.7 (340.7 - 469.2) mg/l (Exposure time: 48 h - Species: Daphnia magna [Static])</td>
</tr>
</tbody>
</table>

12.2. Persistence and Degradability No additional information available.

12.3. Bioaccumulative Potential

### Sodium chloride (7647-14-5)

| BCF fish 1 | (no bioaccumulation) |

12.4. Mobility in Soil No additional information available.

12.5. Other Adverse Effects

Other Information: Avoid release to the environment.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste Disposal Recommendations: Dispose of waste material in accordance with all local, regional, national, and international regulations.

SECTION 14: TRANSPORT INFORMATION

14.1. In Accordance with DOT Not regulated for transport.

14.2. In Accordance with IMDG Not regulated for transport.

14.3. In Accordance with IATA Not regulated for transport.

SECTION 15: REGULATORY INFORMATION

15.1 US Federal Regulations

<table>
<thead>
<tr>
<th>Adenosine (58-61-7)</th>
<th>Listed on the United States TSCA (Toxic Substances Control Act) inventory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride (7647-14-5)</td>
<td>Listed on the United States TSCA (Toxic Substances Control Act) inventory</td>
</tr>
<tr>
<td>Water (7732-18-5)</td>
<td>Listed on the United States TSCA (Toxic Substances Control Act) inventory</td>
</tr>
</tbody>
</table>

15.2 US State Regulations Neither this product nor its chemical components appear on any US state lists.

SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Revision Date: 01/19/2015

Other Information: This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200.

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

SDS US (GHS HazCom)